In September 2021, Hubei Maikang Biotechnology Co., Ltd. was established in Wuhan Optics Valley Biotechnology Park, and successfully introduced a number of enterprise level strategic partners and investors. The founder of the enterprise has many years of overseas market operation experience, and the core start-up team members are elites in different fields with many years of R & D, investment and operation experience.

Maikang's strategic target 

Based on China, facing the world and taking Wuhan as the base point, strive to establish a marketing network covering major large and medium-sized cities in China in one year. Simultaneously spread over the overseas core market.

Market size

With the common market view and values as the link, we will recruit talents and invite elites in about one year, establish more than 30 directly affiliated and franchise management institutions, and establish more than 1000 community operated stores. In about two years, we will achieve more than 10,000 stores.

Product chain

Focus on the health field of cardiovascular and cerebrovascular diseases and chronic diseases, pay attention to people with high disability and death, and continue to supply high-quality products to meet rigid demand and cost-effective consumption.

Value goal

Benefit the general public with the best quality and favorable price. In 1-2 years, benefit at least 10 million people, with an annual output value of more than 100 billion and tax payment of more than 10 billion, and achieve more than 100,000 successful entrepreneurs.